Status:
RECRUITING
Implementing Precision Medicine in cOmmunity HospiTALs
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Metastatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting
Detailed Description
Patients will be selected to present a metastatic cancer (de novo or relapse after primary tumor treatment) eligible for a first line treatment (chemotherapy, immunotherapy, endocrine therapy or targe...
Eligibility Criteria
Inclusion
- Participants are eligible to be included in the study only if they meet all of the following criteria:
- Age ≥ 18 years
- Histology: solid malignant tumor
- Locally advanced/unresectable and/or metastatic (for prostate cancer: castration resistant prostate cancer, for RH+/HER2- breast cancer: prior treatment with endocrine therapy plus anti-CDK4/6 inhibitor)
- Eastern Cooperative Oncology Group (ECOG) performance status \< 2
- Measurable disease as per RECIST criteria
- Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code)
- Voluntary signed and dated written informed consent prior to any study specific procedure.
Exclusion
- Participants will be excluded from the study if they meet any of the following criteria:
- Radiological evidence of symptomatic or progressive brain metastases
- Previous or current malignancies of others histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin and prostate cancer
- Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol
- Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
- Minors (Age \< 18 years)
- Pregnant or breast-feeding women
- Previous enrollment in the present study.
Key Trial Info
Start Date :
June 29 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 15 2030
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT05283044
Start Date
June 29 2022
End Date
April 15 2030
Last Update
June 25 2025
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
CH de la Côte Basque
Bayonne, France, 64100
2
CH de Bligny
Bligny, France
3
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, France, 33300
4
CH Sud Francilien
Corbeil-Essonnes, France, 91106